



(51) International Patent Classification:

A61P 35/00 (2006.01) C07K 14/47 (2006.01)

(21) International Application Number:

PCT/US2022/033344

(22) International Filing Date:

14 June 2022 (14.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/211,364 16 June 2021 (16.06.2021) US

(71) Applicant: **EMPIRICO INC.** [US/US]; 4660 La Jolla Village Drive, Suite 100, San Diego, California 92122 (US).

(72) Inventors: **GOTTESMAN, Omri**; 4660 La Jolla Village Drive, Suite 100, San Diego, California 92122 (US). **BRUSE, Shannon**; 4660 La Jolla Village Drive, Suite 100, San Diego, California 92122 (US). **BUSKE, Paul**; 4660 La Jolla Village Drive, Suite 100, San Diego, California 92122 (US). **CAJES, Brian**; 4660 La Jolla Village Drive, Suite 100, San Diego, California 92122 (US). **JAKUBOSKY, David**; 4660 La Jolla Village Drive, Suite 100, San Diego, California 92122 (US). **KLEINSTEIN, Sarah**; 4660 La

Jolla Village Drive, Suite 100, San Diego, California 92122 (US). **LEWIS, David**; 4660 La Jolla Village Drive, Suite 100, San Diego, California 92122 (US). **ROZEMA, David**; 4660 La Jolla Village Drive, Suite 100, San Diego, California 92122 (US). **VEKICH, John**; 4660 La Jolla Village Drive, Suite 100, San Diego, California 92122 (US).


(74) Agent: **BOYLE ANDERSON, Erin**; WILSON SONSINI, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: TREATMENT OF MST1 RELATED DISEASES AND DISORDERS

FIG. 1



(57) Abstract: Disclosed herein are compositions comprising an oligonucleotide that targets MST1. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MST1 mutations that include providing an oligonucleotide that targets MST1 to a subject.

[Continued on next page]

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*